Conference Coverage
CMSC MRI guidelines evolve into international consensus protocol
Internationally accepted consensus guidelines will improve lagging conformity with the recommendations.
News
Relapsing, progressive MS classifications should be abandoned
“The disease appears to be more of a continuum of disability progression, which is sometimes also accompanied by relapses.”
News
FDA approves Uplizna for treatment of anti-AQP4 antibody–positive NMOSD
Second FDA-approved therapy for neuromyelitis optica spectrum disorder offers patients additional treatment option.
Conference Coverage
Cannabis misconceptions still common among MS clinicians
Studies and surveys underscore that misconceptions about cannabis could be common among clinicians and patients.
Conference Coverage
Function in MS may vary significantly within EDSS scores
Mean normalized velocity of preferred walking speed may vary by more than 20% within EDSS groups and overlap by more than 20% between groups.
Conference Coverage
Herpes zoster infection with MS treatment higher in women?
While MS affects more women than men, the fivefold increase in HZV well exceeds the female-male ratio in MS.
Conference Coverage
Newest oral DMTs haven’t yet made a big impact in the MS world
“Now there are six oral DMTs competing among themselves for a relatively limited pool of patients.”
Conference Coverage
Constraint-induced movement therapy may boost neuroplasticity in MS
For patients with asymmetric upper limb nonuse, the treatment “is highly successful for promoting increased use by the more-affected arm.”
Conference Coverage
Telerehabilitation may be effective in MS
Patients with MS may achieve equivalent benefits and increased cost savings with telerehabilitation, compared with outpatient rehabilitation.
Conference Coverage
No benefit of three commonly used medications for MS fatigue
These findings will hopefully encourage doctors to “think twice before prescribing these medications that could be harmful and have no clear...
Conference Coverage
Ofatumumab shows high elimination of disease activity in MS
The once-per-month self-injected therapy could offer an alternative to DMTs that require in-office infusion.
Conference Coverage
Natalizumab switch to moderate-efficacy DMT increases disability risk
“Patients transitioning from natalizumab to another high-efficacy therapy have better inflammatory and disability outcomes, compared with those...
Conference Coverage
High levels of air pollution linked to increased MS risk
“Countermeasures that cut air pollution can be important for public health, not only to reduce deaths related to cardiac and pulmonary diseases...
Conference Coverage
Natalizumab bests fingolimod for relapsing-remitting MS
More patients taking natalizumab versus fingolimod reached NEDA at one year.
Conference Coverage
Serum NfL in early MS can help predict clinical course
Higher serum NfL within 5 years of MS diagnosis carries a higher risk of long term-clinical disability and higher risk of developing progressive...
Conference Coverage
Initial high-efficacy MS therapy tied to less disability later
Conference Coverage
Cautionary findings on acquired immunodeficiency from anti-CD20 MS therapy
Clinicians are advised to monitor patients with MS much closer for signs of hypogammaglobulinemia and lymphopenia starting with year 2 on therapy...
Conference Coverage
-
CMSC MRI guidelines evolve into international consensus protocol -
-
-
-
Newest oral DMTs haven’t yet made a big impact in the MS world
Multimedia
Question 1 of 5